Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional S...
November 13 2019 - 4:10PM
FOR IMMEDIATE RELEASE
Affimed Announces Closing of Public
Offering of Common Shares and Exercise of Underwriters’ Option to
Purchase Additional Shares
Heidelberg, Germany, November 13, 2019 – Affimed
N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical stage
biopharmaceutical company committed to giving patients back their
innate ability to fight cancer, today announced the closing of its
previously announced public offering of 12,000,000 common shares,
at the public offering price of $2.50 per share, and the exercise
in full by the underwriters of their option to purchase an
additional 1,800,000 common shares. The exercise of the option to
purchase additional shares brought the total number of common
shares sold by Affimed to 13,800,000 common shares and increased
the gross proceeds raised in the offering, before deducting
underwriting discounts and commissions and estimated expenses of
the offering payable by Affimed, to $34.5 million.
Jefferies LLC and SVB Leerink LLC are acting as
joint book-running managers and SunTrust Robinson Humphrey, Inc.
and Laidlaw & Company (UK) Ltd. as co-managers of the offering.
A shelf registration statement relating to these securities filed
with the Securities and Exchange Commission (the “SEC”) was
declared effective by the SEC on November 7, 2018. The offering was
made only by means of a prospectus and prospectus supplement. A
prospectus supplement and accompanying prospectus related to the
offering have been filed with the SEC and are available at the
SEC’s website located at www.sec.gov. Copies of the prospectus
supplement and accompanying prospectus related to the offering may
be obtained by contacting Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, or by telephone at (877) 821-7388, or by email at
Prospectus_Department@Jefferies.com, or SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at (800) 808-7525, ext. 6132, or by email at
syndicate@svbleerink.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of, these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical stage
biopharmaceutical company committed to giving patients back their
innate ability to fight cancer. Affimed’s fit-for-purpose ROCK®
platform allows innate cell engagers to be designed for specific
patient populations. The Company is developing single and
combination therapies to treat hematologic and solid tumors.
Forward-looking Statements
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “will,” “would” and similar
expressions. Forward-looking statements appear in a number of
places throughout this release and include statements regarding our
intentions, beliefs, projections, outlook, analyses and current
expectations concerning, among other things, the value of our ROCK®
platform, our ongoing and planned preclinical development and
clinical trials, our collaborations and development of our products
in combination with other therapies, the timing of and our ability
to make regulatory filings and obtain and maintain regulatory
approvals for our product candidates our intellectual property
position, our collaboration activities, our ability to develop
commercial functions, expectations regarding clinical trial data,
our results of operations, cash needs, financial condition,
liquidity, prospects, future transactions, growth and strategies,
the industry in which we operate, the trends that may affect the
industry or us and the risks uncertainties and other factors
described under the heading “Risk Factors” in Affimed’s filings
with the SEC. Given these risks, uncertainties and other factors,
you should not place undue reliance on these forward-looking
statements, and we assume no obligation to update these
forward-looking statements, even if new information becomes
available in the future.
Affimed Investor and Media Contact:Gregory Gin,
Head of Investor RelationsE-Mail: IR@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024